MK-7602: a potent multi-stage dual-targeting antimalarial
Paola Favuzza(The University of Melbourne), Alan F. Cowman(Walter and Eliza Hall Institute of Medical Research), Zhiyu Lei, John A. McCauley(Fox Chase Cancer Center), Anthony N. Hodder(The University of Melbourne), Nicholas Murgolo(Merck & Co., Inc., Rahway, NJ, USA (United States)), Josephine Palandri(Gomal University), Lionel Brice Feufack-Donfack(Institut Pasteur du Cambodge), Andrew Danziger(United States Military Academy), Marissa Vavrek(United States Military Academy), Ágnes Orbán(Institut Pasteur du Cambodge), Maria V. Fawaz(United States Military Academy), Anthony T. Papenfuss(The University of Melbourne), Anna Ngo(Walter and Eliza Hall Institute of Medical Research), James McCarthy(Walter and Eliza Hall Institute of Medical Research), Rachael Coyle(Wellcome Sanger Institute), Justin A. Boddey(The University of Melbourne), Richard W. Birkinshaw(The University of Melbourne), Brad E. Sleebs(The University of Melbourne), Kitsanapong Reaksudsan(The University of Melbourne), Tony Triglia(Walter and Eliza Hall Institute of Medical Research), Ryan Steel(The University of Melbourne), Jean Popovici(Université Paris Cité), Jocelyn Sietsma Penington(Walter and Eliza Hall Institute of Medical Research), Kym N. Lowes(The University of Melbourne), Madeline G. Dans(Burnet Institute), S.W. Scally(Walter and Eliza Hall Institute of Medical Research), Michael Kelly(Commonwealth Scientific and Industrial Research Organisation), Jerzy M. Dziekan(Walter and Eliza Hall Institute of Medical Research), Christopher W. Boyce(Scripps Research Institute), Jonathan A. Robbins(United States Military Academy), Nicole Sevilleno(Wellcome Sanger Institute), Lee M(Columbia University Irving Medical Center), Lianyun Zhao(United States Military Academy), Zhuyan Guo(United States Military Academy), Jennifer K. Thompson(Walter and Eliza Hall Institute of Medical Research), David B. Olsen, Wendy Bailey(United States Military Academy), Manuel de Lera Ruiz(United States Military Academy)
Cited by 6
Related Papers
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
|Science Translational Medicine|2015|541
Antibiotic Susceptibility Profiles of <i>Escherichia coli</i> Strains Lacking Multidrug Efflux Pump Genes
|Antimicrobial Agents and Chemotherapy|2001|502
Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2
|The EMBO Journal|2020|499
Selective small-molecule inhibition of an RNA structural element
|Nature|2015|419